Oct 7, 20211 min readIMBRUVICA Treatment for Waldenstroms Macroglobulinemia *LIVE Dinner* 10/12/21See attached event flyerInviteUpdated_PCY-03144_10.pdfDownload PDF • 1.24MB
The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade1-3
Combined Power to Change the Game: RYBREVANT® + LAZCLUZE™ in First-Line Treatment of EGFR+* Locally Advanced or mNSCLC ~ Thursday, 10/24/24
![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
Comments